JNJ-75276617 for Acute Myeloid Leukemia
This trial is testing a new drug to see what dose is safe to use with other treatments for AML. They will also expand to study the safety and tolerability of the new drug at the recommended Phase 2 dose.
- Acute Myeloid Leukemia
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there any US-based locations that are hosting this experiment?
"Currently, 7 medical centres are recruiting participants for this study. These can be found in Duarte, Birmingham and Los Angeles as well as four other locations across the US. It is wise to pick a trial site close by so that travelling becomes minimal if you decide to participate."
Are there still available slots in this trial for participants?
"According to the info posted on clinicaltrials.gov, this investigation is currently recruiting patients. The trial was initially listed on October 4th 2022 and its details were most recently amended on December 1st of the same year."
How many participants are currently enrolled in this research?
"Affirmative. According to information on clinicaltrials.gov, this trial is still enrolling participants and was initially posted at the beginning of October 2022 with its last update happening in December of that year. The medical research calls for 150 patients from 7 different sites."
Has the FDA sanctioned JNJ-75276617 for public use?
"Our team at Power believe that JNJ-75276617 carries a safety rating of 1 due to the limited evidence available in Phase 1 trials, which typically provide only preliminary data on both efficacy and security."
What objectives is this clinical trial hoping to accomplish?
"The primary objective of the two-year clinical trial is to evaluate participant's experiences with adverse events. Secondary objectives include recording patient responses in terms of complete remission with partial hematologic recovery (CRh) meeting certain criteria, calculating how many participants experience depletion of leukemic blasts, and observing any changes in expression levels among menin-KMT2A target genes."